Systemic Administration of Acazicolcept, a Dual CD28 and Inducible T cell Costimulator Inhibitor, Ameliorates Experimental Autoimmune Uveitis

PURPOSE: Combined inhibition of CD28 and inducible T cell costimulator (ICOS) pathways with acazicolcept (ALPN-101) represents a potential new treatment for uveitis. Here, we evaluate preclinical efficacy using experimental autoimmune uveitis (EAU) in Lewis rats. METHODS: Efficacy was tested in 57 L...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Leslie, Lewis, Katherine E., Evans, Lawrence S., Dillon, Stacey R., Pepple, Kathryn L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2023
Materias:
Uveitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064916/
https://www.ncbi.nlm.nih.gov/pubmed/36976157
http://dx.doi.org/10.1167/tvst.12.3.27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064916/
https://www.ncbi.nlm.nih.gov/pubmed/36976157
http://dx.doi.org/10.1167/tvst.12.3.27

Ejemplares similares